

## HeraBEAT and HeraCARE now operational across multiple Hapvida sites

- HeraBEAT monitor and cloud based pregnancy monitoring platform customised HeraCARE PRO platform operational across multiple Hapvida hospitals and clinics
- Uptake from medical professionals being witnessed across multiple locations - patient data being uploaded and shared between HeraBEAT and HeraCARE PRO platform daily (see image one and two below)
- Pilot trial validates solution scalability and potential - HeraMED to provide updates as trial progresses
- HeraMED continues discussions with Hapvida medical professionals regarding feedback and trial initiatives


Medical technology company, **HeraMED Limited (ASX:HMD)** ("HeraMED" or the "Company") is pleased to provide an update on the trial of its smart medical grade foetal heart rate monitor HeraBEAT, and its cloud based SaaS pregnancy monitoring platform HeraCARE PRO, with one of Brazil's largest healthcare providers Hapvida Saude (Hapvida).


Following the successful integration of HeraCARE PRO into Hapvida's IT systems (refer ASX announcement: 1 July 2019), HeraMED advises that its HeraBEAT devices and the Company's HeraCARE PRO platform are now operational at multiple locations and being utilised by medical professionals and patients as part of a broader pilot trial.

Hapvida is one of Brazil's largest healthcare providers and medical insurance companies. The group services over 6.5 million customers annually, through a network of over 100 hospitals and 1,000 clinics across 11 states.

HeraMED is now witnessing seamless data upload and sharing between the operational HeraBEAT monitors and the customised HeraCARE PRO platform from Hapvida. This development outlines the potential scalability of both solutions and further validates the Company's potential with large scale medical organisations.

Both Hapvida and HeraMED remain in ongoing discussions regarding ongoing platform updates and optimisation. Both parties will aim to utilise the solutions during the intrapartum phase of pregnancy, which is the period spanning childbirth, from the onset of labour. Should this be successful, it will provide even greater value to the platform and potentially underpin increased uptake.





**Image one and two:** Data upload between HeraBEAT monitor and HeraCARE PRO showing mother (lower) and foetal heart rates (upper)

HeraMED will remain in ongoing discussions with Hapvida's medical professionals to gather feedback on the HeraBEAT device and HeraCARE solution. The Company will update shareholders as developments associated with the trial progress.

**CEO and Co-founder Mr David Groberman said:** "Having multiple HeraBEAT monitors and HeraCARE subscriptions deployed and operational across Hapvida's network marks a significant achievement for HeraMED.

"The broader pilot trial with Hapvida will utilise HeraCARE PRO and HeraBEAT to provide a cost-effective and more accurate pregnancy monitoring offering to patients and medical professionals in Brazil.

"Management will continue its dialogue with Hapvida and its teams of medical professionals on the status of the trial and endeavour to update shareholders as developments progress."

**-ENDS-**

HeraMED Limited

CEO and Co-Founder

David Groberman

M: +972-52-6991188

E: David@hera-med.com

Company Secretary

Stephen Buckley

T: +61 (0)8 6189 1155

E: stephen@companysecsol.com.au

**Released through:** Henry Jordan, Six Degrees Investor Relations, +61 431 271 538

#### **About Hapvida Saude:**

Founded in 1979, Hapvida Saude is one of Brazil's largest healthcare providers, medical insurance companies and hospital owners. Hapvida currently services over 6.5 million customers per annum, through its network of over 100 hospitals and 1,000 clinics across 11 states.

#### **About HeraMED Limited (ASX:HMD):**

HeraMED Limited is an innovative medical technology company delivering smart pregnancy monitoring solutions for home and professional use. HeraMED provides peace of mind to expecting parents by solving challenges associated with the reliability and accessibility of pre-natal care. Through development and utilisation of end-to-end medical grade solutions, HeraMED overcomes the barriers of high-cost and shortage of fundamental services, enabling smart monitoring devices, cloud-based platform and AI capabilities

HeraMED is commercialising its smart medical grade ultrasound monitoring device, HeraBEAT. The device has passed multiple clinical trials and secured approval by key regulatory bodies including TGA (Australia), CE (Europe) and AMAR (Israel) for commercial sale.

The Company has partnerships with two leading medical organisations, the Mayo Clinic and TEVA Pharmaceutical Industries Inc. (NYSE: TEVA). HeraMED diversifying its product range and services with the launch of SaaS services and cloud based monitoring systems.